Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Teens with rare swelling disorder get new drug tested

NCT ID NCT05511922

Disease control Sponsor: KalVista Pharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a new oral medication (sebetralstat) works in the bodies of 11 teenagers aged 12 to 17 with hereditary angioedema (HAE) types I or II. The goal was to measure drug levels and timing in the blood. All participants were already in a larger HAE trial. The study is complete and helps guide dosing for younger patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

11 people

The number who actually took part.

Started

Oct 2022

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adolescent patient 12 to 17 years of age at the time of enrollment and during sample collection in this PK subtrial. * Patient is currently participating in KVD900-302. * Patient must provide signed informed consent or assent (when applicable), and a legally authorized representative (LAR) must also provide signed informed consent when applicable. * Patient and LAR are willing and able to provide samples per the requirements of the protocol, including willingness to complete forms and the electronic Diary, obtain and return samples in a timely manner, and obtain samples while within the required age limit. Exclusion Criteria: * Patient has a history of any bleeding disorder or currently taking any anti-coagulant or anti-platelet agent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary angioedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary angioedema

Contacts and locations

Locations

  • KalVista Investgative Site

    Auckland, 1023, New Zealand

  • KalVista Investgative Site

    Frimley, GU16 7UJ, United Kingdom

  • KalVista Investigative Site

    Scottsdale, Arizona, 85251, United States

  • KalVista Investigative Site

    Little Rock, Arkansas, 72205, United States

  • KalVista Investigative Site

    San Diego, California, 92122, United States

  • KalVista Investigative Site

    San Diego, California, 92123, United States

  • KalVista Investigative Site

    Santa Monica, California, 90404, United States

  • KalVista Investigative Site

    Centennial, Colorado, 80112, United States

  • KalVista Investigative Site

    Colorado Springs, Colorado, 80907, United States

  • KalVista Investigative Site

    Evansville, Indiana, 47715, United States

  • KalVista Investigative Site

    Overland Park, Kansas, 66211, United States

  • KalVista Investigative Site

    Louisville, Kentucky, 40215, United States

  • KalVista Investigative Site

    Chevy Chase, Maryland, 20815, United States

  • KalVista Investigative Site

    Plymouth, Minnesota, 55446, United States

  • KalVista Investigative Site

    St Louis, Missouri, 63141, United States

  • KalVista Investigative Site

    Charlotte, North Carolina, 28277, United States

  • KalVista Investigative Site

    Cincinnati, Ohio, 45236, United States

  • KalVista Investigative Site

    Toledo, Ohio, 43617, United States

  • KalVista Investigative Site

    Dallas, Texas, 75231, United States

  • KalVista Investigative Site

    Layton, Utah, 84041, United States

  • KalVista Investigative Site

    Spokane, Washington, 99204, United States

  • KalVista Investigative Site

    Campbelltown, 2560, Australia

  • KalVista Investigative Site

    Vienna, 1090, Austria

  • KalVista Investigative Site

    Sofia, 1431, Bulgaria

  • KalVista Investigative Site

    Montreal, H2W 1R7, Canada

  • KalVista Investigative Site

    Grenoble, 38043, France

  • KalVista Investigative Site

    Lille, 59037, France

  • KalVista Investigative Site

    Paris, 75012, France

  • KalVista Investigative Site

    Berlin, 12203, Germany

  • KalVista Investigative Site

    Frankfurt, 60590, Germany

  • KalVista Investigative Site

    Mainz, 55131, Germany

  • KalVista Investigative Site

    Mörfelden-Walldorf, 64546, Germany

  • KalVista Investigative Site

    Athens, 11521, Greece

  • KalVista Investigative Site

    Athens, 11527, Greece

  • KalVista Investigative Site

    Haifa, 31048, Israel

  • KalVista Investigative Site

    Petach Tikvah, 4920235, Israel

  • KalVista Investigative Site

    Ramat Gan, 52621, Israel

  • KalVista Investigative Site

    Tel Aviv, 64239, Israel

  • KalVista Investigative Site

    Sapporo, Hokkaido, 002-8072, Japan

  • KalVista Investigative Site

    Chiba, 260-8677, Japan

  • KalVista Investigative Site

    Hiroshima, 730-8518, Japan

  • KalVista Investigative Site

    Kawagoe-shi, 350-8550, Japan

  • KalVista Investigative Site

    Maebashi, 371-8511, Japan

  • KalVista Investigative Site

    Soka-shi, 340-0041, Japan

  • KalVista Investigative Site

    Takatsuki-shi, 569-8686, Japan

  • KalVista Investigative Site

    Tokyo, 142-8666, Japan

  • KalVista Investigative Site

    Yokohama, 236-0004, Japan

  • KalVista Investigative Site

    Amsterdam, 1105 AZ, Netherlands

  • KalVista Investigative Site

    Sângeorgiu de Mureş, 547530, Romania

  • KalVista Investigative Site

    Martin, 036 59, Slovakia

  • KalVista Investigative Site

    Cape Town, 7700, South Africa

  • KalVista Investigative Site

    Barcelona, 08035, Spain

  • KalVista Investigative Site

    Barcelona, 08907, Spain

  • KalVista Investigative Site

    Madrid, 28046, Spain

  • KalVista Investigative Site

    Birmingham, B9 5SS, United Kingdom

  • KalVista Investigative Site

    Cambridge, CB2 0QQ, United Kingdom

  • KalVista Investigative Site

    Cardiff, CF14 4XW, United Kingdom

  • KalVista Investigative Site

    Leeds, LS9 7TF, United Kingdom

  • KalVista Investigative Site

    London, E1 2ES, United Kingdom

  • KalVista Investigative Site

    London, NW3 2QG, United Kingdom

  • Kalvista Investigative Site

    Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.